S0820, Adenoma and Second Primary Prevention Trial
Run by SWOG Cancer Research Network · NCT01349881 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2027-09-15.
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 354 (actual) |
| Sponsor | SWOG Cancer Research Network Research network |
| Drugs / interventions | Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac |
| Locations | 989 sites (United States) |
| Trial ID | NCT01349881 on ClinicalTrials.gov |
What this trial studies
The purpose of this study is to assess whether the combination of eflornithine 500 mg and sulindac 150 mg (compared to corresponding placebos) has efficacy against colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, any adenomas \>/= 0.3 cm, total advanced colorectal events, or total colorectal events.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * History of Stage 0-III colon or rectal cancer with primary resection 1 year previously * Post-operative colonoscopy and CT scans of chest, abdomen \& pelvis showing no evidence of disease * Must not have cardiovascular risk factors including unstable angina, history of myocardial infarction, or cerebrovascular accident, coronary artery bypass surgery, or NY Heart Assoc Class III or IV heart failure. * Patients must not have known uncontrolled hyperlipidemia (defined as LDL-C \>/= 190 mg/dL or triglycerides \>/= 500 mg/dL within the past 3 years or uncontrolled high blood pressure (systolic blood pressure \> 150 mm Hg) within 28 days prior to registration * At least 30 days from completion of adjuvant chemo and RT. * Presence of gastroesophageal reflux disease acceptable if controlled with medications * Not receiving or planning to receive concomitant intravenous corticosteroids on a regular basis,nonsteroidal anti-inflammatory drugs (NSAIDs), nor anticoagulants on a regular predictable intermittent basis. NSAID use must not exceed 10 days per month; Maximum aspirin dose * 100 mg per day or ≤ two 325 mg tablets per week. Inhaled steroids (i.e. for asthma or related conditions) are allowed. * Able to swallow oral medications * Laboratory: WBC ≥ 4.0 x 1000/mcL, platelets ≥ 100,000/mcL and hemoglobin \> 11.0 g/dL. (A total WBC ≥ 3.1 x 1000/mcL is allowed for non-Hispanic black males and total WBC ≥ 3.4 x 1000/mcL for non-Hispanic black females. Serum bilirubin ≤ 2.0 mg/dL and AST (SGOT) or ALT(SGPT) ≤ 2 x IULN. Serum creatinine ≤ 1.5 x IULN * Zubrod PS 0-1, 18 years of age or older * Will not participate in any other clinical trial for the treatment or prevention of cancer unless off protocol treatment, on follow-up phase only * Offered opportunity to participate in blood specimen banking Exclusion Criteria: * History of colon resection \> 40 cm * Mid-low rectal cancer * Recurrent or metastatic disease * High cardiovascular risk; Uncontrolled hypertension * Planned radiation therapy or additional chemotherapy * Documented history of gastric/duodenal ulcer within last 12 months and/or current treatment or active symptoms of gastric/duodenal ulcer * Known history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or inflammatory bowel disease * ≥ 30 dB uncorrectable hearing loss for age of any of the five tested frequencies on prestudy audiogram * Known hypersensitivity to sulindac or excipient byproducts. Previous asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs * Significant medical or psychiatric condition that would preclude study completion (8 years) * No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for \> 5 years * Pregnant or nursing women. Women/men of reproductive potential must agree to use effective contraception
Where it's running
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States -
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States -
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States -
Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States -
Alaska Regional Hospital
Anchorage, Alaska, United States -
Alaska Women's Cancer Care
Anchorage, Alaska, United States
Show 44 more locations
-
Katmai Oncology Group
Anchorage, Alaska, United States -
Providence Alaska Medical Center
Anchorage, Alaska, United States -
Fairbanks Memorial Hospital
Fairbanks, Alaska, United States -
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States -
Cancer Center at Saint Joseph's
Phoenix, Arizona, United States -
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona, United States -
Banner University Medical Center - Tucson
Tucson, Arizona, United States -
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States -
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, United States -
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, United States -
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States -
Highlands Oncology Group - Rogers
Rogers, Arkansas, United States -
Kaiser Permanente-Anaheim
Anaheim, California, United States -
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, United States -
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California, United States -
Sutter Auburn Faith Hospital
Auburn, California, United States -
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, United States -
Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States -
Kaiser Permanente-Bellflower
Bellflower, California, United States -
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States -
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States -
Mills-Peninsula Medical Center
Burlingame, California, United States -
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, United States -
East Bay Radiation Oncology Center
Castro Valley, California, United States -
Eden Hospital Medical Center
Castro Valley, California, United States -
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California, United States -
Enloe Medical Center
Chico, California, United States -
University Oncology Associates
Clovis, California, United States -
UC Irvine Health Cancer Center-Newport
Costa Mesa, California, United States -
Sutter Davis Hospital
Davis, California, United States -
City of Hope Comprehensive Cancer Center
Duarte, California, United States -
Epic Care-Dublin
Dublin, California, United States -
Kaiser Permanente Dublin
Dublin, California, United States -
Bay Area Breast Surgeons Inc
Emeryville, California, United States -
Epic Care Partners in Cancer Care
Emeryville, California, United States -
Kaiser Permanente-Fontana
Fontana, California, United States -
Kaiser Permanente-Fremont
Fremont, California, United States -
Valley Medical Oncology Consultants-Fremont
Fremont, California, United States -
Kaiser Permanente-Fresno
Fresno, California, United States -
Kaiser Permanente - Harbor City
Harbor City, California, United States -
Kaiser Permanente-Irvine
Irvine, California, United States -
UC San Diego Moores Cancer Center
La Jolla, California, United States -
UCI Health Laguna Hills
Laguna Hills, California, United States -
Loma Linda University Medical Center
Loma Linda, California, United States
+939 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Jason A. Zell, D.O., MPH — University of California, Irvine
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.